News Archive

USTMA Consortium National Virtual Meeting

By | Sunday, September 6, 2020 - 7:34am

The United States Thrombotic Microangiopathy (USTMA) Consortium patient meeting held virtually on Saturday, August 22, 2020 was extremely informative.  The all day meeting format was set up very well allowing patients to ask questions.  Some excellent information, from experts in the field, was shared about TTP history, research, preventing relapse, the effects on the brain, particular issues for women, etc.  Recordings from the meeting are available on their website here. 

Rare Disease Day 2020

By Sydney Kodatsky | Friday, May 22, 2020 - 7:18am

Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. 

ASH FAQs re: COVID-19 and Thrombotic Thrombocytopenic Purpura

By Sydney Kodatsky | Tuesday, April 21, 2020 - 6:49am

The American Society of Hematology (ASH) has posted FAQs regarding new considerations for TTP treatment during the COVID -19 pandemic. This information is available on their website. Input from Drs. Spero Cataland, Paul Coppo, Marie Scully, Masanori Matsumoto, James George, Bernhard Lämmle, Flora Peyvandi, and Ravi Sarode.

Medscape Releases a CME Accredited Activity About TTP

By Sydney Kodatsky | Sunday, April 5, 2020 - 5:42am

Medscape, a well known global online platform for the medical community, has added a new CME (Continuing Medical Education) accredited activity to increase knowledge about the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP) entitled "Advances in iTTP: How Can New Therapeutic Options Improve Patient Care?" .

2020 Research Proposal Deadline EXTENDED

By Sydney Kodatsky | Friday, March 20, 2020 - 2:14pm

Due to the COVID-19 pandemic, the 2020 Answering TTP research grant competition deadline has been extended at least two months, until June 1, 2020. As the situation continues to evolve we will consider further extensions. Take care.

Caplacizumab is Approved by Health Canada

By Sydney Kodatsky | Monday, March 2, 2020 - 11:00pm

March 2, 2020: Caplacizumab has been approved by Health Canada for the treatment of adults with aTTP in combination with plasma echange and immunosuppressive therapy. Answering TTP Foundation is looking forward to working with provincial and territorial partners to ensure that this therapy is quickly made available at TTP treatment centers across the country and receives timely reimbursement by public and private plans.
 
Support Groups

Update on Pilot Program -- Virtual Peer Support Pilot Videoconference

By Sydney Kodatsky | Wednesday, January 29, 2020 - 1:51pm

The first Virtual Peer Support session was held on Jan 16, 2020 and was a success! We had a total of eight participants from Canada and the U.S.A., which made for some meaningful time to learn and share from each other. Participants included those diagnosed with TTP (both recently and dating back years) and family members.

Our next session will be help on May 14, 2020. Again, call in details will be circulated about a week prior to the date via Community Annoucement to the Answering TTP Community.

Pages